NovaBridge Biosciences (NBP) Accumulated Expenses (2021 - 2025)

NovaBridge Biosciences (NBP) has 5 years of Accumulated Expenses data on file, last reported at $2.8 million in Q4 2025.

• Accumulated Expenses for Q4 2025 came in at $2.8 million, up 5.71% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.8 million (up 5.71% YoY), and the FY2025 annual result was $2.8 million, up 5.71% from the prior year.
• Accumulated Expenses grew to $2.8 million in Q4 2025 per NBP's latest filing, from $2.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $8.2 million in Q4 2021 and troughed at $2.6 million in Q4 2024.
• A 5-year average of $5.3 million and a median of $6.1 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses grew 10.41% in 2023, then slumped 61.07% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $8.2 million in 2021, then declined by 25.58% to $6.1 million in 2022, then increased by 10.41% to $6.8 million in 2023, then tumbled by 61.07% to $2.6 million in 2024, then gained by 5.71% to $2.8 million in 2025.
• Business Quant data shows NBP's Accumulated Expenses at $2.8 million in Q4 2025, $2.6 million in Q4 2024, and $6.8 million in Q4 2023.